A key molecular mechanism drives the growth of liver cell cancer while simultaneously suppressing the body's immune response ...
New research shows that reducing dietary protein may significantly lower liver cancer risk or slow its progression in people ...
Researchers assess the cost‐effectiveness of nivolumab plus ipilimumab vs lenvatinib or sorafenib for hepatocellular ...
People with compromised liver function may be able to reduce their risk of liver cancer or slow its progression with a simple dietary change: eating less protein. A Rutgers-led study in Science ...
CHICAGO — For the first time, doctors say they have found a pill that improves survival in liver cancer, a notoriously hard-to-treat disease diagnosed in more than half a million people globally each ...
A research team from the School of Clinical Medicine of the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) has pioneered the use of a 'dual immunotherapy' combination—nivolumab and ...
Cancer of the liver, seen in a radial cross-section abdominal scan. (Photo by: BSIP/Universal Images Group via Getty Images) The number of new liver cancer cases will nearly double in the next 25 ...
Hepatocellular carcinoma (HCC) is the most common subtype of primary liver cancer and continues to be a major cause of cancer ...
Liver cancer is increasingly affecting non-drinkers in India. Doctor explains how fatty liver disease, diabetes, hepatitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results